Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

The presentation of chronic myeloid leukemia (CML) can be variable and related to the
phase of the disease. It can manifest a wide range of symptoms and signs; ocular …

Small molecule therapy is a critical component of targeted anticancer treatment, with
tyrosine kinase inhibitors (TKIs) being the first compounds to treat the clonal Chronic …

Aims Adherence to therapy is a key factor in successful treatment. The aim of this systematic
review is to assess the extent to which patients with better adherence to oral therapy have …

Purpose Suboptimal adherence to tyrosine kinase inhibitors (TKIs) contributes to poor
clinical outcomes in chronic myeloid leukemia (CML). This randomised controlled trial (RCT) …

Objectives To obtain insight into patients' reasons for medication (non) adherence in chronic
myeloid leukaemia (CML) and needs and wishes regarding information and communication …

Classical homocystinuria (HCU) is the most common inborn error of metabolism in Qatar,
with an incidence of 1: 1800, and is caused by the Qatari founder p. R336C mutation in the …

Protein tyrosine phosphatase receptor gamma (PTPRG) is a member of the receptor-like
family protein tyrosine phosphatases and acts as a tumor suppressor gene in different …

Background: The economic outcome research of approved tyrosine kinase inhibitors for
treating the chronic phase of chronic myeloid leukemia in developing is scarce. The aim of …

Background: Chronic myeloid leukemia (CML) represents about one quarter of leukemia
cases in our region making it a great challenge to the health system. Aims: Since adherence …